LOG IN
SIGN UP
MARKET
NBIX
NBIX
Neurocrine Biosciences Inc
NASDAQ
109.24
+2.52
+2.36%
Closed 18:49 10/04 EDT
OPEN
107.85
PREV CLOSE
106.72
HIGH
112.12
LOW
107.68
VOLUME
1.48M
TURNOVER
--
52 WEEK HIGH
112.12
52 WEEK LOW
71.88
MARKET CAP
10.45B
P/E (TTM)
917.98
1D
5D
1M
3M
1Y
5Y
Neurocrine Biosciences Appoints Dr. Ingrid Delaet as Chief Regulatory Officer
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that Dr. Ingrid Delaet will join the company's executive management team as Chief Regulatory Officer effective October 1, leading the regulatory affairs, quality assurance, medical writing, and pr...
PR Newswire · 5d ago
The Market Slumped Last Week; Why IBD Stock Of The Day Neurocrine Biosciences Didn't
Neurocrine Biosciences is the IBD Stock Of The Day as market uncertainty shakes plenty leading of equities — but not NBIX stock.
Investor's Business Daily · 09/26 20:22
4 Analysts Have This to Say About Neurocrine Biosciences
Within the last quarter, Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings:
Benzinga · 09/26 14:43
Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2022
Upgrades
Benzinga · 09/26 14:02
Neurocrine initiated Equal Weight at Wells Fargo despite upcoming catalysts
Wells Fargo has launched its coverage on Neurocrine Biosciences (NASDAQ:<a href="https://seekingalpha.com/symbol/NBIX?utm_medium=referral&utm_source=webull.com" title="Neurocrine Biosciences, Inc." target=...
Seekingalpha · 09/26 13:43
Wells Fargo Initiates Coverage On Neurocrine Biosciences with Equal-Weight Rating, Announces Price Target of $110
Wells Fargo analyst Mohit Bansal initiates coverage on Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight rating and announces Price Target of $110.
Benzinga · 09/26 11:28
Wells Fargo Starts Neurocrine Biosciences at Equalweight With $110 Price Target
Wells Fargo Starts Neurocrine Biosciences at Equalweight With $110 Price Target
MT Newswires · 09/26 07:41
IBD 50 Stocks To Watch: Biotech Leader Neurocrine Biosciences Eyes New Buy Point
Among the top stocks to watch today's stock market, biotech leader Neurocrine Biosciences is nearing a new buy point.
Investor's Business Daily · 09/21 16:33
About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligram (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women, and ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.
Webull offers kinds of Neurocrine Biosciences, Inc. stock information, including NASDAQ:NBIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBIX stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading NBIX stock methods without spending real money on the virtual paper trading platform.